Boston Scientific Corp. of Natick says new real-world data shows better survival rates for patients using its implantable cardiac devices than clinical trials suggested.
The company’s Altitude Clinical Science program analyzes outcomes data from patients using BSX’s Latitude Patient Management system. An analysis of nearly 86,000 patients showed five-year survival rates of up to 92 percent for patients using implantable cardioverter defibrillators and up to 78 percent for those using cardiac resynchronization therapy difibrillators.
The company said more than 130,000 patients have used the Latitude system since it was introduced in 2006. It presented the new data at the Heart Rhythm Society Scientific Sessions in Boston.
